Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GERTRUDE: Genetically-informed Therapy for ER+ Breast Cancer
NCT05933395Phase 2Recruiting
- Sponsor
- Dartmouth Health
- Start
- Sep 2024
- Primary completion
- Oct 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib, alpelisib, everolimus, abemaciclib in breast cancer, sponsored by Dartmouth Health. Started Sep 2024; status: recruiting.
02
Drugs
neratinibalpelisibeverolimusabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05933395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933395.